Figure 4.
In vitro radiosensitizing efficiencies of small-molecule and encapsulated drugs. Radiation dose-dependent clonogenic survival curves recorded for (a) H460 lung cancer and (b) PC3 prostate cancer cells after being treated with therapeutic dose (i.e., IC50; see Table S3) of (i) small-molecule (“free”)/encapsulated Wtmn or Dtxl, (ii) small-molecule Dtxl and Wtmn in different administration orders, and (iii) encapsulated Dtxl and Wtmn (either dual-drug-loaded NPs or a combination of two single-drug-loaded NPs. (N.B. n.s. denotes statistical nonsignificance; * denotes p < 0.05, i.e., statistical significance.)